Back to dashboard
CommercialCoverageHigh impact

Prostate Cancer Screening (CPB 0521, reviewed 2025-11-25)

Aetna·Urology, Oncology, Internal Medicine +2 more·Medical Policy
Effective date
Nov 25, 2025
We identified it
Aug 14, 2026
Days to comply
—

Summary

Aetna's updated Prostate Cancer Screening policy (CPB 0521) clarifies coverage for PSA screening and digital rectal examinations while establishing a comprehensive list of experimental/unproven tests that are NOT covered. The policy maintains coverage for standard PSA testing (CPT 84152, 84153, 84154) and DRE (G0102, G0103) for eligible age groups, but explicitly excludes 25+ alternative screening tests including PCA3, four-kallikrein panel, Stockholm3, and genetic-based screening tests. Billing teams must immediately stop submitting claims for the listed experimental codes and ensure claims use only the covered CPT/HCPCS codes when medical necessity criteria are met.

Action Required

Action needed
Effective immediately (2025-11-25): Billing team must perform the following: (1) Update billing software to DENY and reject all claims for the 25+ experimental/investigational prostate cancer screening codes listed in the policy, including 0021U, 0133U, 0433U, 0495U, 81210, 81313, 81539, 83520, 84255, and all related molecular cytogenetics codes (88271-88275, 88291). (2) Configure system to ONLY allow billing for covered codes (84152, 84153, 84154, G0102, G0103) when the following criteria are documented: patient age 45+ (average risk) or 40+ (high-risk: African-American or family history), with life expectancy ≥10 years if age 75+. (3) Create a claim-scrubbing rule to automatically flag and reject any of the excluded tests before submission. (4) Notify all providers in urology and primary care specialties of the non-covered tests list via email with specific code list attached. (5) Update encounter forms and EMR templates to remove checkboxes for experimental tests (PCA3, four-kallikrein panel, Stockholm3, genetic screening, etc.). (6) Train billing staff to educate patients at check-in that experimental prostate screening tests are not covered by Aetna and patient will be responsible for full cost if pursued. Failure to implement these changes will result in: (a) claim denials that cannot be appealed, (b) patient balance billing issues, (c) compliance violations. Priority: Complete software updates and provider notification within 5 business days.

Affected Billing Codes

84152
84153
84154
G0102
G0103
81210
81313
81539
83520
84255
88271
88272
88273
88274
88275
88291